Aclaris Therapeutics (ACRS) Lowered to Sell at BidaskClub

BidaskClub cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a report published on Wednesday, December 20th.

A number of other research firms also recently commented on ACRS. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a buy rating in a research report on Friday, December 15th. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a buy rating to a hold rating in a research report on Wednesday, October 11th. JMP Securities reaffirmed an outperform rating and issued a $39.00 target price on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, ValuEngine cut shares of Aclaris Therapeutics from a hold rating to a sell rating in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $39.20.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up $0.09 on Wednesday, hitting $25.51. 113,972 shares of the company traded hands, compared to its average volume of 292,909. The company has a market capitalization of $764.91 and a P/E ratio of -11.81. Aclaris Therapeutics has a 12 month low of $21.32 and a 12 month high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $2.00 million. equities research analysts anticipate that Aclaris Therapeutics will post -2.59 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACRS. Vanguard Group Inc. lifted its stake in shares of Aclaris Therapeutics by 17.6% during the 1st quarter. Vanguard Group Inc. now owns 711,519 shares of the biotechnology company’s stock valued at $21,218,000 after buying an additional 106,303 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Aclaris Therapeutics by 6.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 2,736 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Aclaris Therapeutics by 1,793.1% during the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 6,760 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Aclaris Therapeutics by 2,828.4% during the 2nd quarter. Sei Investments Co. now owns 11,040 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 10,663 shares in the last quarter. Finally, TD Asset Management Inc. lifted its stake in shares of Aclaris Therapeutics by 15.6% during the 2nd quarter. TD Asset Management Inc. now owns 17,100 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 2,304 shares in the last quarter. Institutional investors own 92.02% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2018/01/11/bidaskclub-lowers-aclaris-therapeutics-acrs-to-sell.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply